Teva Pharmaceutical Industries Limited (TLV:TEVA)
6,202.00
-158.00 (-2.48%)
May 13, 2025, 5:24 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $3.89B USD in the quarter ending March 31, 2025, with 1.89% growth. This brings the company's revenue in the last twelve months to $16.62B, up 3.82% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.62B
Revenue Growth
+3.82%
P/S Ratio
1.19
Revenue / Employee
$465.62K
Employees
35,686
Market Cap
73.61B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Danel (Adir Yeoshua) | 2.77B |
Kamada | 586.24M |
Bait Bakfar | 103.40M |
Novolog (Pharm-Up 1966) | 2.02B |
Ilex Medical | 920.37M |
SofWave Medical | 235.09M |
BrainsWay | 149.39M |
InterCure | 238.85M |
Teva Pharmaceutical Industries News
- 1 day ago - Why Teva Pharmaceuticals Stock Blasted 6% Higher Today - The Motley Fool
- 1 day ago - Teva upgraded to Overweight at J.P. Morgan on margin clarity - Seeking Alpha
- 5 days ago - Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside - Seeking Alpha
- 6 days ago - Why Teva Pharmaceutical Stock Is Soaring Today - The Motley Fool
- 6 days ago - Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says - Barrons
- 6 days ago - Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum - Benzinga
- 6 days ago - Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum - Benzinga
- 6 days ago - Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties - CNBC